Matsumoto et al. [107] evaluated MUC-1, a membrane-associated mucin, in pancreatic juice samples from 39 patients with malignant pancreatic mass and 31 patients with benign pancreatic mass in order to study the clinical impact of this biomarker. This evidence concerns the gene MUC5AC and cancer.